Asset sale Announced
Royalty Pharma acquisition of PTC Therapeutics' remaining royalty on Roche's Evrysdi
US$240m consideration
Announced 6 Jan 2026
Advisers
PTC Therapeutics' remaining royalty on Roche's Evrysdi
Target
Not disclosed
- Target
- PTC Therapeutics' remaining royalty on Roche's Evrysdi
- Acquirer
- Royalty Pharma
- Seller
- PTC Therapeutics
- Buyer based in
- United States
- Seller based in
- United States
- Sector
- Specialty finance and leasing
- Tags
- Specialty finance and leasing, Pharma, Life Sciences
In the league tables
Similar deals
- DRI Healthcare Trust acquisition of Royalty participation rights in U.S. net sales of tavapadon Sep 2026 · US$316m · Specialty finance and leasing
- Ligand Pharmaceuticals acquisition of XOMA Royalty Apr 2026 · US$739m · Specialty finance and leasing
- HealthCare Royalty acquisition of Modeyso commercial sales royalties Apr 2026 · Specialty finance and leasing
- Royalty Pharma acquisition of Neurimmune's royalty interest in AstraZeneca's cliramitug Jul 2026 · US$250m · Pharma
- Aurobindo acquisition of Lannett Jul 2026 · US$250m · Pharma
